Cargando…

Establishing the Medical Actionability of Genomic Variants

Actionability is an important concept in medicine that does not have a well-accepted standard definition, nor is there a general consensus on how to establish it. Medical actionability is often conflated with clinical utility, a related but distinct concept. This lack of clarity contributes to pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Goddard, Katrina A.B., Lee, Kristy, Buchanan, Adam H., Powell, Bradford C., Hunter, Jessica Ezzell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184682/
https://www.ncbi.nlm.nih.gov/pubmed/35363504
http://dx.doi.org/10.1146/annurev-genom-111021-032401
_version_ 1785042194016501760
author Goddard, Katrina A.B.
Lee, Kristy
Buchanan, Adam H.
Powell, Bradford C.
Hunter, Jessica Ezzell
author_facet Goddard, Katrina A.B.
Lee, Kristy
Buchanan, Adam H.
Powell, Bradford C.
Hunter, Jessica Ezzell
author_sort Goddard, Katrina A.B.
collection PubMed
description Actionability is an important concept in medicine that does not have a well-accepted standard definition, nor is there a general consensus on how to establish it. Medical actionability is often conflated with clinical utility, a related but distinct concept. This lack of clarity contributes to practice variation and inconsistent coverage decisions in genomic medicine, leading to the potential for systematic bias in the use of evidence-based interventions. We clarify how medical actionability and clinical utility are distinct and then discuss the spectrum of actionability, including benefits for the person, the family, and society. We also describe applications across the life course, including prediction, diagnosis, and treatment. Current challenges in assessing the medical actionability of identified genomic variants include gaps in the evidence, limited contexts with practice guidelines, and subjective aspects of medical actionability. A standardized and authoritative assessment of medical actionability is critical to implementing genomic medicine in a fashion that improves population health outcomes and reduces health disparities.
format Online
Article
Text
id pubmed-10184682
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-101846822023-05-15 Establishing the Medical Actionability of Genomic Variants Goddard, Katrina A.B. Lee, Kristy Buchanan, Adam H. Powell, Bradford C. Hunter, Jessica Ezzell Annu Rev Genomics Hum Genet Article Actionability is an important concept in medicine that does not have a well-accepted standard definition, nor is there a general consensus on how to establish it. Medical actionability is often conflated with clinical utility, a related but distinct concept. This lack of clarity contributes to practice variation and inconsistent coverage decisions in genomic medicine, leading to the potential for systematic bias in the use of evidence-based interventions. We clarify how medical actionability and clinical utility are distinct and then discuss the spectrum of actionability, including benefits for the person, the family, and society. We also describe applications across the life course, including prediction, diagnosis, and treatment. Current challenges in assessing the medical actionability of identified genomic variants include gaps in the evidence, limited contexts with practice guidelines, and subjective aspects of medical actionability. A standardized and authoritative assessment of medical actionability is critical to implementing genomic medicine in a fashion that improves population health outcomes and reduces health disparities. 2022-08-31 2022-04-01 /pmc/articles/PMC10184682/ /pubmed/35363504 http://dx.doi.org/10.1146/annurev-genom-111021-032401 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See credit lines of images or other third-party material in this article for license information
spellingShingle Article
Goddard, Katrina A.B.
Lee, Kristy
Buchanan, Adam H.
Powell, Bradford C.
Hunter, Jessica Ezzell
Establishing the Medical Actionability of Genomic Variants
title Establishing the Medical Actionability of Genomic Variants
title_full Establishing the Medical Actionability of Genomic Variants
title_fullStr Establishing the Medical Actionability of Genomic Variants
title_full_unstemmed Establishing the Medical Actionability of Genomic Variants
title_short Establishing the Medical Actionability of Genomic Variants
title_sort establishing the medical actionability of genomic variants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184682/
https://www.ncbi.nlm.nih.gov/pubmed/35363504
http://dx.doi.org/10.1146/annurev-genom-111021-032401
work_keys_str_mv AT goddardkatrinaab establishingthemedicalactionabilityofgenomicvariants
AT leekristy establishingthemedicalactionabilityofgenomicvariants
AT buchananadamh establishingthemedicalactionabilityofgenomicvariants
AT powellbradfordc establishingthemedicalactionabilityofgenomicvariants
AT hunterjessicaezzell establishingthemedicalactionabilityofgenomicvariants